English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Objective : To evaluate the possible effect of  reldesemtiv , a fast skeletal muscle troponin activator, on prescription and acceptance of durable medical equipment (DME) in the FORTITUDE-ALS trial.  Methods:  Health economic outcome information was collected in FORTITUDE-ALS (NCT03160898); sites recorded if and when DME, specifically manual or power wheelchairs, gastrostomy tubes, noninvasive ventilators, or augmentative language devices, was prescribed by a physician and accepted by the patient (DME-PAP) during the trial. Acceptance was defined as the patient agreeing the item was needed. Cox regression analysis compared time to DME-PAP for each  reldesemtiv  dose with placebo. Post hoc analyses evaluated all  reldesemtiv  doses compared with placebo.  Results:  At least one DME item was prescribed and accepted by 33/114 (28.9%) of placebo patients, 19/112 (17.0%) of patients receiving  reldesemtiv  150 mg bid, 24/113 (21.2%) receiving 300 mg bid, and 29/117 (24.8%) receiving 450 mg bid. The proportion of new DME-PAP was significantly lower in patients receiving  reldesemtiv  150 mg bid vs placebo (17.0% vs 28.9%,  p  = 0.032). The hazard ratio versus placebo for accepting at least one DME item for all  reldesemtiv  doses combined was 0.61 (confidence interval: 0.39, 0.96,  p  = 0.032). 25% of placebo patients were prescribed and agreed to obtain a DME item by 84 days; this threshold was met for  reldesemtiv -treated patients at 120 days.  Conclusions:  Results suggest ALS patients receiving  reldesemtiv  may have lower risk of and delayed need for DME related to impaired mobility, breathing, swallowing, or speaking; this delay is consistent with other measures indicating delay in disease progression.

amyotrophic lateral sclerosis and frontotemporal degeneration

Prescription and acceptance of durable medical equipment in FORTITUDE-ALS, a study of  reldesemtiv  in ALS: post hoc analyses of a randomized, double-blind, placebo-controlled clinical trial